(Q40517221)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7736687%20AND%20SRC:MED&resulttype=core&format=json

24 October 2019

review article

1 reference

title

Clinical pharmacokinetics of rifabutin (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7736687%20AND%20SRC:MED&resulttype=core&format=json

24 October 2019

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7736687%20AND%20SRC:MED&resulttype=core&format=json

24 October 2019

author name string

M H Skinner

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7736687%20AND%20SRC:MED&resulttype=core&format=json

24 October 2019

publication date

1 February 1995

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7736687%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacokinetics

24 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7736687%20AND%20SRC:MED&resulttype=core&format=json

24 October 2019

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7736687%20AND%20SRC:MED&resulttype=core&format=json

24 October 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7736687%20AND%20SRC:MED&resulttype=core&format=json

24 October 2019

page(s)

115-125

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7736687%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.2165/00003088-199528020-00003

24 October 2019

exact match

0 references

cites work

The activity of rifabutin against Mycobacterium leprae

1 reference

12 December 2020

Rifampin and ansamycin interactions with cyclosporine after renal transplantation

1 reference

12 December 2020

Dynamic aspects of the in vitro chemotherapeutic activity of ansamycin (rifabutine) on mycobacterium intracellulare

1 reference

12 December 2020

Rifabutin prophylaxis against Mycobacterium avium complex infection

1 reference

12 December 2020

The serum rifabutin concentrations in a patient successfully treated for multi-resistant Mycobacterium tuberculosis infection

1 reference

12 December 2020

Rifabutin in the treatment of cavitary lung disease due to Mycobacterium gordonae

1 reference

12 December 2020

1 reference

12 December 2020

Rifabutin (ansamycin LM427) for the treatment of pulmonary Mycobacterium avium complex

1 reference

12 December 2020

Dose-limiting toxicity of rifabutin in AIDS-related complex: syndrome of arthralgia/arthritis

1 reference

12 December 2020

Absorption, disposition and preliminary metabolic pathway of 14C-rifabutin in animals and man.

1 reference

12 December 2020

Mycobacterium avium complex infections in patients with the acquired immunodeficiency syndrome

1 reference

12 December 2020

Effectiveness of the macrolide clarithromycin in the treatment of Mycobacterium avium complex infection in HIV-infected patients

1 reference

12 December 2020

Extracellular and intracellular activity of sparfloxacin against Mycobacterium avium complex and Mycobacterium xenopi

1 reference

12 December 2020

Therapeutic implications of inhibition versus killing of Mycobacterium avium complex by antimicrobial agents

1 reference

12 December 2020

Rifabutin Prophylaxis and Uveitis

1 reference

12 December 2020

Susceptibility of Mycobacterium kansasii to ethambutol and its combination with rifamycins, ciprofloxacin and isoniazid

1 reference

12 December 2020

Uveitis associated with rifabutin prophylaxis

1 reference

12 December 2020

The early bactericidal activity of rifabutin measured by sputum viable counts in Hong Kong patients with pulmonary tuberculosis

1 reference

12 December 2020

The in-vitro bactericidal activities of combinations of antimicrobial agents against clinical isolates of Mycobacterium avium-intracellulare

1 reference

12 December 2020

In vitro susceptibility of Mycobacterium avium complex and Mycobacterium tuberculosis strains to a spiro-piperidyl rifamycin

1 reference

12 December 2020

In vitro susceptibility of Campylobacter jejuni to 27 antimicrobial agents and various combinations of beta-lactams with clavulanic acid or sulbactam

1 reference

12 December 2020

Killing by antimycobacterial agents of AIDS-derived strains of Mycobacterium avium complex inside cells of the mouse macrophage cell line J774.

1 reference

12 December 2020

In vitro susceptibility of Mycobacterium avium complex to antibacterial agents

1 reference

12 December 2020

Pharmacokinetics of rifabutin

1 reference

12 December 2020

Disseminated tuberculosis of the central nervous system responsive to rifabutin.

1 reference

12 December 2020

Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS.

1 reference

12 December 2020

Efficacy of rifabutin in the treatment of AIDS-related complex

1 reference

12 December 2020

Rifabutin absorption in humans: relative bioavailability and food effect

1 reference

12 December 2020

Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects

1 reference

12 December 2020

Rifabutin treatment for tuberculosis patients with liver function abnormalities

1 reference

12 December 2020

Comparative in vitro and in vivo activity of rifabutin and rifampicin against Mycobacterium avium complex

1 reference

12 December 2020

Combined chemotherapy including rifabutin for rifampicin and isoniazid resistant pulmonary tuberculosis. G.E.T.I.M. (Group for the Study and Treatment of Resistant Mycobacterial Infection)

1 reference

12 December 2020

Evaluation of the Antiviral Effect of Rifabutin in AIDS-Related Complex

1 reference

12 December 2020

In vitro activity of new rifamycins against rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteria

1 reference

12 December 2020

[Resistance testing of M. avium-intracellulare and M. tuberculosis of AIDS patients with new drugs and drug combinations]

1 reference

12 December 2020

Susceptibility of Mycobacterium malmoense to antibacterial drugs and drug combinations

1 reference

12 December 2020

A study of the effects of rifabutin on isoniazid pharmacokinetics and metabolism in healthy volunteers

1 reference

12 December 2020

Urinary metabolites of rifabutin, a new antimycobacterial agent, in human volunteers

1 reference

12 December 2020

Antimicrobial activity of rifabutin in combination with two and three other antimicrobial agents against strains of Mycobacterium paratuberculosis

1 reference

12 December 2020

Extrapulmonary and disseminated infections due to Mycobacterium malmoense: case report and review

1 reference

12 December 2020

In vivo activities of newer rifamycin analogs against Mycobacterium avium infection

1 reference

12 December 2020

Comparative in vitro activities of MDL 473, rifampin, and ansamycin against Mycobacterium intracellulare

1 reference

12 December 2020

Treatment of nontuberculous mycobacterial infections in pediatric patients

1 reference

12 December 2020

In VitroActivity of Clarithromycin Alone or in Combination with Other Antimicrobial Agents againstMycobacterium avium-intracellulare.Complex Strains Isolated from AIDS Patients

1 reference

12 December 2020

Fluconazole and enhanced effect of rifabutin prophylaxis

1 reference

12 December 2020

A sensitive method for quantitation of rifabutin and its desacetyl metabolite in human biological fluids by high-performance liquid chromatography (HPLC)

1 reference

12 December 2020

Determination of ansamycin MICs for Mycobacterium avium complex in liquid medium by radiometric and conventional methods

1 reference

12 December 2020

New rifamycins modified at positions 3 and 4. Synthesis, structure and biological evaluation

1 reference

12 December 2020

Rifabutine: minimal inhibitory and bactericidal concentrations for Mycobacterium tuberculosis

1 reference

12 December 2020

Identification of urinary metabolites of rifamycin LM 427 in man

1 reference

12 December 2020

Autoinduction of rifabutin metabolism in man.

1 reference

12 December 2020

Rifabutin in combination with clofazimine, isoniazid and ethambutol in the treatment of AIDS patients with infections due to opportunist mycobacteria. Groupe d'Etude et de Traitement des Infections à Mycobacteries Résistantes

1 reference

12 December 2020

Activities of clarithromycin, sulfisoxazole, and rifabutin against Mycobacterium avium complex multiplication within human macrophages

1 reference

12 December 2020

Rifabutin (ansamycin LM 427): a new rifamycin-S derivative for the treatment of mycobacterial diseases

1 reference

12 December 2020

Pharmacokinetics of oral and intravenous rifampicin during chronic administration

1 reference

12 December 2020

Partition data of penicillins determined by means of reversed-phase thin-layer chromatography

1 reference

12 December 2020

[Intra-macrophagic activity of antibiotics combinations against Mycobacterium marinum]

1 reference

12 December 2020

Effect of rifabutin on the phagocytosis and intracellular growth of Mycobacterium intracellulare in mouse resident and activated peritoneal and alveolar macrophages

1 reference

12 December 2020

In vitro activities of new rifamycin derivatives against Mycobacterium tuberculosis and M. avium complex

1 reference

12 December 2020

Activity of clarithromycin against Mycobacterium avium complex infection in beige mice

1 reference

12 December 2020

Emergence during unsuccessful chemotherapy of multiple drug resistance in a strain of Mycobacterium tuberculosis

1 reference

12 December 2020

Determination of in vitro susceptibility of mycobacteria to ansamycin

1 reference

12 December 2020

10.2165/00003088-199528020-00003

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7736687%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

24 October 2019

1037710882

0 references

1 reference